Hospital

Moderna is completing regulatory submissions for mRNA-1273.214 in preparation for the fall booster season, based on clinical data showing that the booster candidate has a significantly higher neutralizing antibody response against all tested variants including Omicron BA.4/5.

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for previously treated HER2-positive breast cancer and gastric or gastroesophageal junction adenocarcinoma.

The FDA's current way of inspecting facilities for quality control is badly outdated and is politically unworkable, unreliable, and unsafe.

A booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1.

Methotrexate is an immunosuppressive agent used to treat cancer, dermatology-, and rheumatology-related issues.

Vibhuti Arya Amirfar, PharmD, MPH, discusses building individual and systems resilience to dismantle structural racism in the pharmacy field.

Experts discuss tools and trainings that health care institutions have established during the pandemic to support hematology-oncology pharmacists who are struggling with wellness and mental health challenges.

Screening participation increased over time, but the increase was smallest among individuals aged 50 to 54.

Rucaparib (Rubraca) is a poly (ADP-ribose) polymerase (PARP) inhibitor used for ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and castration-resistant prostate cancer.

The non-estrogen pill was first approved by the FDA in 1973.

Joe Duarte, co-founder and president of ContinuumMD, discusses a program model that allows pharmacies to provide virtual and in-person primary care options for rural communities with health care access challenges.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses how pharmacists can support patients with cancer who have a much higher risk of heart disease.

Emphasizing the accessible nature of pharmacies and why this is essential for patients can help legislators and others understand why changes are necessary.

Harnessing the current momentum and engaging with legislators is crucial for the pharmacy industry to grow and expand.

Ofatumumab (Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis.

Women in pharmacy must realize that what they have to offer has value, both to the business and to patients’ lives.

Finding the time to improve payer performance can be a major hurdle but designating even 30 minutes per week can make a difference.

David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.

Simple changes to each day can improve motivation and wellness for pharmacists.

Christine Walko, PharmD, BCOP, FCCP, discusses some new developments for PARP inhibitors in cancer care for patients with homologous recombination deficiency.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses the relationship between heart disease and cancer and the importance of the field of cardio-oncology when treating patients with cancer.

Findings suggest that the HER2 L755S mutation plays a role in the aggressiveness of lobular breast cancer observed in the clinic.

Autologous stem cell transplantation was underutilized in community settings for mantle cell lymphoma.

Survey results show 40% of health care leaders believe a lack of communication between prescribers and pharmacists is preventing the successful management of patients’ medications.

Paxlovid treats COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss research conducted looking to assess the hematology-oncology pharmacist “great migration” from the field.